GSK fights back against Senate's "flawed" Avandia report
25 February 2010
Asher Mullard
GlaxoSmithKline has leapt to the defence of its once-blockbuster diabetes drug Avandia (rosiglitazone) after it came under fire earlier this week from a US Senate inquiry into the drug's safety (
scripnews.com,...
Please Login to read the full article.